Literature DB >> 8095178

A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus.

I J Jacobs1, S A Smith, R W Wiseman, P A Futreal, T Harrington, R J Osborne, V Leech, A Molyneux, A Berchuck, B A Ponder.   

Abstract

Linkage analysis in familial breast and ovarian cancer and studies of allelic deletion in sporadic ovarian tumors have suggested that chromosome 17q may be the location of a gene of importance in ovarian carcinogenesis. We have examined tumor and normal DNA samples from 120 patients with ovarian tumors for allelic deletion at 12 loci on chromosome 17q. Allelic deletion was observed in 64 cases (53%) of which 56 showed loss of heterozygosity at all loci analyzed on 17q. The pattern of allele loss at metastatic sites was consistent with loss of heterozygosity having occurred prior to metastasis. A common region of deletion, defined by 6 cases of invasive epithelial ovarian cancer and a benign serous cystadenoma, spanned 16 cM and was delimited by nm23 and GH. This region is distal to the region on chromosome 17q to which the familial breast/ovarian cancer susceptibility gene has been mapped. The results suggest that a tumor suppressor gene involved in sporadic ovarian carcinogenesis is located on the distal portion of chromosome 17q and is distinct from the gene linked to familial cases.

Entities:  

Mesh:

Year:  1993        PMID: 8095178

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Molecular genetics of familial breast-ovarian cancer.

Authors:  E J van Rensburg; B A Ponder
Journal:  J Clin Pathol       Date:  1995-09       Impact factor: 3.411

2.  Tumour suppressor genes in ovarian cancer.

Authors:  W Foulkes
Journal:  BMJ       Date:  1993-10-16

3.  Monoallelic expression of the insulin-like growth factor-2 gene in ovarian cancer.

Authors:  K Yun; M Fukumoto; Y Jinno
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

4.  A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1.

Authors:  A K Godwin; L Vanderveer; D C Schultz; H T Lynch; D A Altomare; K H Buetow; M Daly; L A Getts; A Masny; N Rosenblum
Journal:  Am J Hum Genet       Date:  1994-10       Impact factor: 11.025

5.  Loss of heterozygosity studies in tumors from families with breast-ovarian cancer syndrome.

Authors:  M Zelada-Hedman; M Torroella; R Mesquita; M Nordenskjöld; L Skoog; A Lindblom
Journal:  Hum Genet       Date:  1994-09       Impact factor: 4.132

6.  The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.

Authors:  Paulina M Wojnarowicz; Kathleen Klein Oros; Michael C J Quinn; Suzanna L Arcand; Karen Gambaro; Jason Madore; Ashley H Birch; Manon de Ladurantaye; Kurosh Rahimi; Diane M Provencher; Anne-Marie Mes-Masson; Celia M T Greenwood; Patricia N Tonin
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

7.  BACH1 Ser919Pro variant and breast cancer risk.

Authors:  Pia Vahteristo; Kristiina Yliannala; Anitta Tamminen; Hannaleena Eerola; Carl Blomqvist; Heli Nevanlinna
Journal:  BMC Cancer       Date:  2006-01-24       Impact factor: 4.430

8.  Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes.

Authors:  Y Hatta; S Takeuchi; J Yokota; H P Koeffler
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Polymerase chain reaction allelotyping of human ovarian cancer.

Authors:  R J Osborne; V Leech
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

10.  Allelic loss on distal chromosome 17p is associated with poor prognosis in a group of Brazilian breast cancer patients.

Authors:  M A Nagai; M M Pacheco; M M Brentani; L A Marques; R R Brentani; B A Ponder; L M Mulligan
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.